Molecule of the Week


February 22, 2010

Bortezomib (trade name Velcade) is a boronic acid that was approved by the US Food and Drug Administration in 2003 as the first drug to treat multiple myeloma, a type of white blood cell cancer. It is a proteazome blocker that is also used to treat mantle cell lymphoma. Bortezomib passed US$1 million in sales in 2008. It has several adverse side effects, and current research is targeting improved proteazome inhibitors.